IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement ...
Their findings highlighted promising results for two of the analyzed biomarkers: Delta-like ligand 3 (DLL3) and Thyroid transcription factor-1 (TTF-1). DLL3 was identified in over 70% of the ...
Ltd. for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program. Under deal terms, IDEAYA will develop and commercialize SHR-4849 worldwide outside of Greater China. The company stated that ...